Imatinib mesylate ameliorates the dystrophic phenotype in exercised mdx mice
| Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
|---|---|
| Data(s) |
19/10/2012
19/10/2012
2009
|
| Resumo |
Myofiber degeneration, inflammation, and fibrosis are remarkable features of Duchenne muscular dystrophy. We hypothesized that the administration of imatinib mesylate, an inhibitor of tyrosine kinase and TGF-beta pro-fibrogenic activity, could improve the muscular conditions in mdx mice. Four-week old mdx mice were treated and exercised for 6 weeks. Gastrocnemius and diaphragm histopathology, strength, creatine kinase, and cytokine levels were evaluated. The treated group presented increased muscular strength and decreased CK levels, injured myofibers, and inflammatory infiltrates. Pro-inflammatory cytokines and TGF-beta were also reduced, while IL-10 was increased, suggesting an immunomodulatory effect of imatinib, which can ameliorate the dystrophic phenotype in mdx mice. (C) 2009 Elsevier B.V. All rights reserved. Petrobras FAPESP AADM University of Ribeirao Preto-UNAERP |
| Identificador |
JOURNAL OF NEUROIMMUNOLOGY, v.212, n.1/Fev, p.93-101, 2009 0165-5728 http://producao.usp.br/handle/BDPI/20373 10.1016/j.jneuroim.2009.05.006 |
| Idioma(s) |
eng |
| Publicador |
ELSEVIER SCIENCE BV |
| Relação |
Journal of Neuroimmunology |
| Direitos |
restrictedAccess Copyright ELSEVIER SCIENCE BV |
| Palavras-Chave | #Duchenne muscular dystrophy #mdx mice #Imatinib mesylate #Fibrosis #Immunomodulation #Transforming growth factor-beta 1 #DUCHENNE MUSCULAR-DYSTROPHY #ABL TYROSINE KINASE #TGF-BETA #CLINICAL-APPLICATIONS #TISSUE PROLIFERATION #LYMPHOCYTE DEPLETION #SKELETAL-MUSCLES #GROWTH-FACTORS #T-LYMPHOCYTE #IN-VITRO #Immunology #Neurosciences |
| Tipo |
article original article publishedVersion |
